Anti-Infectives · LP-042
Sulfamethoxazole + Trimethoprim Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-042Anti-Infectives
- Generic identity
- Sulfamethoxazole + TrimethoprimTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-042
- Generic identity
- Sulfamethoxazole + Trimethoprim
- Presentation
- Tablet
- Catalogue strength
- 400 mg + 80 mg; 800 mg + 160 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic combination identity: sulfamethoxazole + trimethoprim.
- Dosage form: tablet.
- Proposed component pairs: 400 mg + 80 mg and 800 mg + 160 mg.
- General catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Exact chemical forms/basis, excipients, coating, score/divisibility and release characteristics.
- Strength-to-pack/SKU mapping and whether both component pairs share one controlled packaging configuration.
- Approved indications, patient eligibility and current product-specific warnings/interactions.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 400 mg sulfamethoxazole + 80 mg trimethoprim | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific SKU mapping not supplied | Keep the two component quantities paired; do not split or cross-combine them. |
| B | 800 mg sulfamethoxazole + 160 mg trimethoprim | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific SKU mapping not supplied | Keep the two component quantities paired; do not split or cross-combine them. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Sulfamethoxazole with trimethoprim, also called co-trimoxazole, combines two antimicrobial ingredients with complementary effects on microbial folate metabolism. It is used for selected susceptible infections and has important allergy, interaction and laboratory-monitoring considerations. A liquid and a tablet are separate presentations of the combination. This page provides general ingredient education, not a Luang Pharma approved indication or a recommendation for self-treatment.
Clinical context and therapeutic role
Its place in therapy depends on the infection, patient immune status, microbiology and local guidance. Some uses require specialist supervision, particularly in immunocompromised patients. The prescriber should consider alternative agents, kidney function, blood disorders and the person’s complete medication list. The catalogue’s strength ratio must be checked against the actual registered presentation. New or worsening respiratory symptoms during treatment deserve prompt clinical attention, not attribution to the infection alone.
Selected safety context
Important risks include severe skin reactions, blood-cell disorders, high potassium, kidney injury and serious allergy. Suspected sulfonamide or trimethoprim allergy, pregnancy, infancy, folate deficiency and glucose-6-phosphate dehydrogenase deficiency require professional assessment. Interactions with warfarin, methotrexate and potassium-raising medicines can be clinically significant. A rash with blisters, fever, unusual bruising, breathlessness, jaundice or marked weakness warrants urgent review. A professional may require laboratory monitoring according to the clinical setting.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Co-trimoxazoleArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Sulfamethoxazole and trimethoprim suspension — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 6 March 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-042.
Professional enquiries
Request product-specific evidence for LP-042.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.